We are aware of an issue causing the title of some ARTG entries to disappear. We are investigating as a priority and hope to have this resolved as soon as possible.
About this guideline
Adopted by the TGA: 28 February 2020
Overseas effective date: 28 January 2017
Note: This document is intended to provide additional clarification relating to the selection and justification of starting materials; and should be read together with ICH guideline S9 on non-clinical evaluation for anticancer pharmaceuticals (ICH S9; EMA/CHMP/ICH/646107/2008)
Categories: ICH | Safety
Non-clinical development
TGA Annotations: Nil
- Where EU guidelines adopted in Australia include references to EU legislation (including EC Directives and Regulations), the requirements contained in the referenced EU legislation are not applicable to the evaluation of medicines by the TGA.
- All documents and other content published by the European Medicines Agency (EMA) on this website are under the copyright and other intellectual property rights ownership of the EMA. Please refer to Legal notice | European Medicines Agency for further information.
For more information see International scientific guidelines adopted in Australia.